Citations

Showing 10 of 108152 citations.

Hippocampal Avoidance Prophylactic Cranial Irradiation: A New Standard of Care?
Brown, Paul D. , Parsons, Michael , Rusthoven, Chad G. , Gondi, Vinai , Parsons, Michael W

Mayo Clinic

Journal of Clinical Oncology | August 11, 2021 | Volume: 39 | Issue: 28 | Pages: 3093-3096

10.1200/jco.21.01632 | PMID 34379456 Get It

Multimodal platform for assessing drug distribution and response in clinical trials
Lopez, Begoña G C, Kohale, Ishwar N. , Du, Ziming , Korsunsky, Ilya , Dai, Yang , Gaglia, Giorgio , Randall, Elizabeth C., Clark, Amanda R. , Marin, Bianca M. , Mladek, Ann C. , Agar, Jeffrey N. , Supko, Jeffrey G. , Wen, Patrick Y. , Lee, Eudocia Q. , Agar, Nathalie Y.R. , Marin, Bianca-Maria, Burgenske, Danielle M. , Grossman, Stuart A , Santagata, Sandro , Sarkaria, Jann, Agar, Nathalie Y R , Marin, Bianca M , Mladek, Ann C , Lopez, Begoña G C, Abdelmoula, Walid M. , Stopka, Sylwia A. , Regan, Michael S. , Basu, Sankha S. , Grossman, Stuart A. , Nabors, Burt , Raychaudhuri, Soumya , Ligon, Keith L , Wen, Patrick Yung , Alexander, Brian M. , Sarkaria, Jann N. , White, Forest M.

Mayo Clinic

Neuro-Oncology | August 11, 2021 | Volume: 24 | Issue: 1 | Pages: 64-77

10.1093/neuonc/noab197 | PMID 34383057 Get It

Abstract Background Response to targeted therapy varies between patients for largely unknown reasons. Here, we developed and applied an integrative platform using mass spectrometry imaging (MSI), phosphoproteomics, and multiplexed tissue imaging for mapping drug distribution, target engagement, and adaptive response to gain insights into heterogeneous response to therapy. Methods Patient-derived xenograft (PDX) lines of glioblastoma were treated with adavosertib, a Wee1 inhibitor, and tissue drug distribution was measured with MALDI-MSI. Phosphoproteomics was measured in the same tumors to identify biomarkers of drug target engagement and cellular adaptive response. Multiplexed tissue imaging was performed on sister sections to evaluate spatial co-localization of drug and cellular response. The integrated platform was then applied on clinical specimens from glioblastoma patients enrolled in the phase 1 clinical trial. Results PDX tumors exposed to different doses of adavosertib revealed intra- and inter-tumoral heterogeneity of drug distribution and integration of the heterogeneous drug distribution with phosphoproteomics and multiplexed tissue imaging revealed new markers of molecular response to adavosertib. Analysis of paired clinical specimens from patients enrolled in the phase 1 clinical trial informed the translational potential of the identified biomarkers in studying patient’s response to adavosertib. Conclusions The multimodal platform identified a signature of drug efficacy and patient-specific adaptive responses applicable to preclinical and clinical drug development. The information generated by the approach may inform mechanisms of success and failure in future early phase clinical trials, providing information for optimizing clinical trial design and guiding future application into clinical practice.
Serum sodium trajectory during AKI and mortality risk
Maggiani‐Aguilera, Pablo , Rondon‐Berrios, Helbert , Pérez-Flores, Christian, Michel-González, Jorge, Torre-Quiroga, Andrés De la, Luna-Ramos, Andrea, Navarro‐Blackaller, Guillermo , Medina-González, Ramón , Chávez Iñiguez, Jonathan Samuel , Kashani, Kianoush , García-García, Guillermo

Mayo Clinic

No container title available | August 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-744279/v1 Get It

Abstract Introduction: Kidneys play a primary role in electrolyte homeostasis. The association between serum sodium level and mortality or the need for kidney replacement therapy during acute kidney injury has not been adequately explored. Methods: In this prospective cohort study, we enrolled patients admitted to the Civil Hospital of Guadalajara from August 2017 to March 2020. We divided patients into five groups based on the serum sodium level trajectories up to ten days following hospitalization, 1) stable normonatremia (serum sodium 135 and 145 mEq/L), 2) fluctuating serum sodium levels (increased/decreased in and out of normonatremia), 3) uncorrected hyponatremia, 4) corrected hyponatremia, and 5) uncorrected hypernatremia. We assessed the association of serum sodium trajectories with mortality and the need for kidney replacement therapy (secondary objective). Results: A total of 288 patients were included. The mean age was 55±18 years, and 175 (60.7%) were male. Acute kidney injury stage 3 was present in 145 (51%). Kidney replacement therapy started in 72 (25%) patients, and 45 (15.6%) died. After adjusting for confounders, 10-day hospital mortality was significantly higher in group 5 (HR, 3.12; 95% CI, 1.05 to 9.24, p = 0.03), and kidney replacement therapy initiation was higher in group 3 (HR, 2.44; 95% CI, 1.04 to 5.70, p = 0.03) compared with group 1. Conclusion: In our prospective cohort, most patients with acute kidney injury had alterations in serum sodium. Uncorrected hypernatremia was associated with death, and uncorrected hyponatremia was correlated with the need for kidney replacement therapy.
Editorial: when to start carvedilol in cirrhosis—time to reconsider? Authors' reply
Wijarnpreecha, Karn , Tao, Cui , Taner, C. Burcin , Tao, Cui , Wijarnpreecha, Karn , Fang, Li , Yang, Liu

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 11, 2021 | Volume: 54 | Issue: 5 | Pages: 728-729

10.1111/apt.16526 | PMID 34379839 Get It

LINKED CONTENTThis article is linked to Wijarnpreecha et al and Gillespie & Hayes papers. To view these articles, visit https://doi.org/10.1111/apt.16490 and https://doi.org/10.1111/apt.16512
Reply by Authors
Liaw, Christine , Khusid, Johnathan A. , Gallante, Blair , Bamberger, Jake N., Atallah, William , Gupta, Mantu , Liaw, Christine W.

Mayo Clinic

Journal of Urology | August 11, 2021 | Volume: 206 | Issue: 5 | Pages: 1239-1239

10.1097/ju.0000000000001948.02 | PMID 34378971 Get It

What men want: Results from a national survey on decision making for prostate cancer treatment and research participation
Osian, Sarah M. Rausch, Bryant, Curtis M., Morris, Christopher G. , Mendenhall, Nancy P. , Hoppe, Bradford S.

Mayo Clinic

Clinical and Translational Science | August 11, 2021 | Volume: 14 | Issue: 6 | Pages: 2314-2326

10.1111/cts.13090 | PMID 34379363 Get It

AbstractData comparing outcomes in prostate cancer and factors affecting treatment choice are sparse. To inform the design of a comparative effectiveness clinical trial, we engaged patients in developing a 28‐question survey about decision making on treatment and research participation and dispersed it among men greater than or equal to 50 years of age. The 1046 respondents ranked long‐term clinical outcomes as most important in making treatment decisions, specific functional outcomes as slightly less important, and duration, location, and cost of treatment as least important. Treatment choice was strongly impacted by side effect profile. Responses to whether the subject would agree to participation in a randomized trial between two types of radiation with minimal differences in outcomes were “yes” in 15%, “no” in 39%, and “undecided” in 46%. Responses to whether the subject would agree to participation in a randomized trial between two treatment durations with similar outcomes were yes in 36%, no in 24%, and undecided in 40%. Findings suggest many potential patients have strong treatment preferences and are averse to randomization, particularly when outcomes of importance may be affected. Patient engagement in study design and novel nonrandomized trial designs may offer a path to increase clinical trial success.
Ultrasensitive and Multiplexed Protein Imaging with Cleavable Fluorescent Tyramide and Antibody Stripping
Pham, Thai , Nazaroff, Christopher D. , Guo, Jia , Guo, Jia , LaBaer, Joshua

Mayo Clinic

International Journal of Molecular Sciences | August 11, 2021 | Volume: 22 | Issue: 16 | Pages: 8644

10.3390/ijms22168644 | PMID 34445351 Get It

Multiplexed single-cell analysis of proteins in their native cellular contexts holds great promise to reveal the composition, interaction and function of the distinct cell types in complex biological systems. However, the existing multiplexed protein imaging technologies are limited by their detection sensitivity or technical demands. To address these issues, here, we develop an ultrasensitive and multiplexed in situ protein profiling approach by reiterative staining with off-the-shelf antibodies and cleavable fluorescent tyramide (CFT). In each cycle of this approach, the protein targets are recognized by antibodies labeled with horseradish peroxidase, which catalyze the covalent deposition of CFT on or close to the protein targets. After imaging, the fluorophores are chemically cleaved, and the antibodies are stripped. Through continuous cycles of staining, imaging, fluorophore cleavage and antibody stripping, a large number of proteins can be quantified in individual cells in situ. Applying this method, we analyzed 20 different proteins in each of ~67,000 cells in a human formalin-fixed paraffin-embedded (FFPE) tonsil tissue. Based on their unique protein expression profiles and microenvironment, these individual cells are partitioned into different cell clusters. We also explored the cell–cell interactions in the tissue by examining which specific cell clusters are selectively associating or avoiding each other.
Prospective evaluation of high‐dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function
Barreto, Jason N. , Thompson, Carrie A. , Mara, Kristin C. , Rule, Andrew D. , Kashani, Kianoush , Leung, Nelson , Larson, Thomas R. , McGovern, Renee M., Witzig, Thomas E. , Frazee, Erin N. , Reid, Joel M. , Thompson, Carrie A , Mara, Kristin C , Rule, Andrew D , Kashani, Kianoush B , Leung, Nelson , Witzig, T.E.

Mayo Clinic

Clinical and Translational Science | August 11, 2021 | Volume: 15 | Issue: 1 | Pages: 105-117

10.1111/cts.13125 | PMID 34378331 Get It

AbstractHigh‐dose methotrexate (HDMTX) pharmacokinetics (PKs), including the best estimated glomerular filtration rate (eGFR) equation that reflects methotrexate (MTX) clearance, requires investigation. This prospective, observational, single‐center study evaluated adult patients with lymphoma treated with HDMTX. Samples were collected at predefined time points up to 96 h postinfusion. MTX and 7‐hydroxy‐MTX PKs were estimated by standard noncompartmental analysis. Linear regression determined which serum creatinine‐ or cystatin C‐based eGFR equation best predicted MTX clearance. The 80 included patients had a median (interquartile range [IQR]) age of 68.6 years (IQR 59.2–75.6), 54 (67.5%) were men, and 74 (92.5%) were White. The median (IQR) dose of MTX was 7.6 (IQR 4.8–11.3) grams. Median clearance was similar across three dosing levels at 4.5–5.6 L/h and was consistent with linear PKs. Liver function, weight, age, sex, concomitant chemotherapy, and number of previous MTX doses did not impact clearance. MTX area under the curve (AUC) values varied over a fourfold range and appeared to increase in proportion to the dose. The eGFRcys (ml/min) equation most closely correlated with MTX clearance in both the entire cohort and after excluding outlier MTX clearance values (r = 0.31 and 0.51, respectively). HDMTX as a 4‐h infusion displays high interpatient pharmacokinetic variability. Population PK modeling to optimize MTX AUC attainment requires further evaluation. The cystatin C‐based eGFR equation most closely estimated MTX clearance and should be investigated for dosing and monitoring in adults requiring MTX as part of lymphoma management.
Removing the blindfold: The centrality of care in caring for patients with multiple chronic conditions
Montori, Víctor M. , Montori, Victor M

Mayo Clinic

Health Services Research | August 11, 2021 | Volume: 56 | Issue: S1 | Pages: 969-972

10.1111/1475-6773.13865 | PMID 34378207 Get It

Pharmacologic Interventions for Fracture Risk Reduction in the Oldest Old: What Is the Evidence?
Sfeir, Jad , Pignolo, Robert J. , Sfeir, Jad G

Mayo Clinic

JBMR Plus | August 11, 2021 | Volume: 5 | Issue: 10 | Pages: No page available

10.1002/jbm4.10538 | PMID 34693190 Get It

ABSTRACT With an increasingly older population, the proportion of patients 85 years or older seeking interventions to protect their musculoskeletal health is growing. Osteoporosis in the geriatric population presents unique diagnostic and therapeutic challenges. Multimorbidity, frailty, falls, polypharmacy, and other neurobehavioral factors influence our approach to fracture prevention in this population. The vast majority of the evidence from clinical trials establish pharmacologic fracture efficacy in postmenopausal women. The evidence is scarce for the oldest old men and women, a population also at risk for adverse events and mortality. Most studies show continued efficacy of pharmacologic interventions in this age group, although they are largely limited by small sample sizes. We herein review the available evidence of pharmacologic interventions for fracture risk reduction in this population and explore the emerging senotherapeutic interventions in the pipeline. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.